Tags: Drug.

Tofogliflozin (USAN codenamed CSG452) is an experimental drug for the treatment of diabetes mellitus and is being developed by Chugai Pharma in collaboration with Kowa and Sanofi. It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2) which is responsible for at least 90% of the glucose reabsorption in the kidney. As of September 2012 the drug is in Phase III clinical trials.

Tofogliflozin_monohydrate_skeletal_3D.svg
ATC prefix
None
CAS number
1201913-82-7
CAS supplemental
(anhydrous)
IUPAC name
(1S3R4S5S6R)-6-(4-Ethylbenzyl)-6'-(hydroxymethyl)-3'4'5'6'-tetrahydro-3H-spiro[2-benzofuran-12'-pyran]-3'4'5'-triol hydrate (1:1)
PubChem
46908928

Loading...

This page contains content from the copyrighted Wikipedia article "Tofogliflozin"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.